1:29:32
Dr. Iliana Lega: Evidence-based approaches to menopause: Overcoming misinformation
Therapeutics Initiative
Overview
This video provides an evidence-based overview of menopause, aiming to debunk common myths and misinformation. It defines menopause as a natural transition, not a disease, and discusses its symptoms, which vary during perimenopause and postmenopause. The presentation highlights the significant knowledge and care gaps surrounding menopause, exacerbated by historical misinterpretations of studies like the Women's Health Initiative (WHI). It details current evidence-based treatments, primarily focusing on menopausal hormone therapy (MHT) as a first-line option for vasomotor symptoms in eligible women, while also exploring non-hormonal treatments and local therapies for genitourinary syndrome. The talk concludes by addressing prevalent myths about disease prevention, bioidentical hormones, and testosterone use, emphasizing the importance of individualized, evidence-based care.
How was this?
Save this permanently with flashcards, quizzes, and AI chat
Chapters
- Menopause is defined as 12 months after the last menstrual period, typically occurring around age 51, with a normal range from 45-55.
- It is a normal, natural physiological transition, not a medical condition, affecting 100% of women who live long enough.
- The transition, known as perimenopause, can last up to 10 years prior to menopause, during which hormone levels fluctuate, often leading to more significant symptoms than postmenopause.
- Symptoms evolve: early perimenopause symptoms are linked to irregular ovulation (mood, sleep, weight gain, heavy bleeding), while later stages are characterized by hypoestrogenic symptoms like hot flashes and night sweats.
Understanding menopause as a natural process, rather than an illness, is crucial for reducing stigma and empowering individuals to seek appropriate care for bothersome symptoms.
A woman in her 40s experiencing irregular periods, mood swings, and sleep disturbances is likely in perimenopause, where symptoms are driven by fluctuating hormones rather than a simple lack of estrogen.
- A significant knowledge gap exists, with many women feeling unprepared and uninformed about menopause, partly due to it being a taboo topic.
- Healthcare providers have historically contributed to a 'care gap,' with many women finding medical consultations unhelpful or their symptoms inadequately addressed.
- The decline in hormone therapy (HT) use since the early 2000s, largely due to the misinterpretation of the WHI study, has led to undertreatment of menopausal symptoms.
- Misinformation is rampant, fueled by social media influencers and commercial products lacking evidence, further confusing patients and providers.
Addressing these gaps is essential to ensure women receive accurate information and effective treatments, preventing unnecessary suffering and promoting well-being during a significant life transition.
A survey showing only 20% of women feel knowledgeable about menopause highlights the widespread lack of understanding and preparedness.
- The WHI was a large randomized controlled trial evaluating hormone therapy safety, primarily in older women (average age 63).
- Initial results reported increased risks of heart disease, stroke, and breast cancer, leading to widespread fear and a dramatic reduction in HT prescriptions.
- A subsequent subgroup analysis of the WHI showed that for women aged 50-59 (recently menopausal), cardiovascular risks were not increased.
- The study's interpretation and media coverage created a lasting negative perception of HT, impacting care for decades despite later clarifications.
Understanding the nuances of the WHI study, particularly the age of participants, is critical for correcting historical misinterpretations that led to the undertreatment of menopausal symptoms.
The WHI study participants were significantly older than the typical age of menopause, meaning the reported risks were not directly applicable to younger, recently menopausal women.
- Treatment is warranted for bothersome menopausal symptoms, not menopause itself; the best evidence supports treatments for vasomotor symptoms (hot flashes, night sweats) and genitourinary syndrome of menopause (GSM).
- Menopausal Hormone Therapy (MHT) is the first-line treatment for vasomotor symptoms in women aged 50-60 within 10 years of menopause, provided there are no contraindications.
- MHT offers benefits beyond symptom relief, including improved sleep, mood, bone health, and GSM, but these are secondary indications for starting therapy.
- Risks of MHT include potential increases in VTE (especially oral estrogen), stroke, and breast cancer, though these risks are generally low and depend on the type, dose, and duration of therapy.
Knowing the evidence-based treatment options allows individuals and clinicians to make informed decisions, prioritizing safety and effectiveness for managing menopausal symptoms.
For a woman experiencing frequent hot flashes and night sweats, MHT is recommended as the most effective treatment, provided she has no contraindications like a history of breast cancer.
- Transdermal estrogens (patches, gels) bypass the liver's first-pass effect, significantly reducing the risk of blood clots (VTE) compared to oral estrogens.
- The 'window of opportunity' for starting MHT (first 10 years post-menopause or before age 60) is primarily related to cardiovascular risk, as estrogen may worsen established atherosclerosis.
- Absolute contraindications to MHT include hormone-sensitive cancers (like ER/PR+ breast cancer) and a history of arterial thrombotic disease (heart attack, stroke).
- Bioidentical hormones have the same chemical structure as endogenous hormones; while many approved products are bioidentical, compounded versions are not recommended due to lack of regulation and evidence.
Understanding the different types of MHT, their specific risks (like VTE with oral vs. transdermal), and contraindications is crucial for safe and personalized treatment.
A woman with a history of deep vein thrombosis would likely be prescribed a transdermal estrogen patch instead of an oral estrogen to minimize her risk of recurrent clotting.
- Non-hormonal systemic treatments include SSRIs/SNRIs, gabapentin (for nighttime symptoms), and newer neurokinin B antagonists (like fezolinetant).
- These are typically reserved for women with contraindications to MHT (e.g., breast cancer survivors) or those who decline hormone therapy after informed consent.
- Neurokinin B antagonists offer targeted relief for vasomotor symptoms but are new, expensive, and lack long-term safety data.
- Genitourinary Syndrome of Menopause (GSM) is best treated with local vaginal estrogen, which is low-dose, minimally absorbed systemically, and does not require progesterone for endometrial protection.
Effective non-hormonal and local treatment options exist, providing alternatives for individuals who cannot or choose not to use systemic hormone therapy.
A breast cancer survivor experiencing severe hot flashes might be prescribed a neurokinin B antagonist or an SSRI if MHT is contraindicated.
- Myth 1: MHT should be used for disease prevention (cardiovascular, Alzheimer's). Evidence does not support this; MHT does not prevent dementia and may increase cardiovascular risk in older women.
- Myth 2: Only bioidentical hormones are safe or effective. Many approved MHT products are bioidentical; the key is the formulation and delivery, not just the term 'bioidentical'. Transdermal estradiol and micronized progesterone are considered safest.
- Myth 3: Every menopausal woman needs testosterone. Systemic testosterone is only recommended for hypoactive sexual desire disorder (HSDD) in menopausal women, with limited evidence for other symptoms like mood or energy.
- Social media claims about MHT preventing dementia or heart disease are often false and not supported by robust scientific evidence.
Correcting these prevalent myths is crucial for guiding patients away from ineffective or potentially harmful treatments and towards evidence-based care.
Claims on social media that hormone therapy prevents Alzheimer's disease are not supported by scientific evidence and contradict findings from major studies.
Key takeaways
- Menopause is a normal life transition, not a disease, and treatment should focus on managing bothersome symptoms.
- The WHI study's initial findings were misinterpreted, leading to widespread undertreatment; recent evidence supports MHT's safety and efficacy for younger, recently menopausal women.
- Transdermal MHT generally carries a lower risk of blood clots than oral MHT, making it a preferred option for many.
- MHT is the most effective treatment for vasomotor symptoms (hot flashes, night sweats) and is also beneficial for genitourinary syndrome, sleep, and mood in appropriate candidates.
- Non-hormonal options like SSRIs/SNRIs and neurokinin B antagonists are available for those who cannot use MHT.
- Local vaginal estrogen is highly effective and safe for treating genitourinary symptoms and does not require progesterone.
- Claims on social media about MHT for disease prevention or testosterone for broad symptom relief are largely unsupported by evidence.
Key terms
MenopausePerimenopauseVasomotor symptomsGenitourinary Syndrome of Menopause (GSM)Menopausal Hormone Therapy (MHT)Women's Health Initiative (WHI)Transdermal estrogenBioidentical hormonesNeurokinin B antagonistsHypoactive Sexual Desire Disorder (HSDD)
Test your understanding
- How is menopause diagnosed, and why is it considered a natural transition rather than a medical condition?
- What were the key findings of the WHI study, and how has the interpretation of its results evolved regarding hormone therapy use in different age groups?
- What are the primary indications for initiating Menopausal Hormone Therapy (MHT), and what are the main risks associated with its use?
- Compare and contrast the risks and benefits of oral versus transdermal estrogen therapy.
- What are the evidence-based treatment options for Genitourinary Syndrome of Menopause (GSM), and why is local vaginal estrogen often preferred?